Is prophylactic treatment after myocardial infarction evidence-based?

Family Practice

Volumn 15, Issue 5, 1998, Pages 457-461

  Brotons, Carlos ^a   Calvo, Francisco ^b   Cascant, Purificació ^b   Ribera, Aida ^b   Moral, Irene ^b   Permanyer Miralda, Gaietà ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b NONE

Author keywords

Myocardial infarction; Primary care; Prophylactic treatment; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; NITRATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIMARY MEDICAL CARE; PROPHYLAXIS; PROSPECTIVE STUDY; RECURRENCE RISK; SECONDARY PREVENTION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICHOLESTEREMIC AGENTS; ASPIRIN; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; EVIDENCE-BASED MEDICINE; FAMILY PRACTICE; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; NITROGLYCERIN; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; SPAIN; VASODILATOR AGENTS;

EID: 0031797196     PISSN: 02632136     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
2. Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Mean J 1998; 9: 8-16.
3. Pfeffer MA, Braunwald E, Moye LA et al. SAVE. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Eng J Med 1992; 327: 669-677.
4. The Acute Infarction Ramipril (AIRE) Study Investigators. Effect of Ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart filure. Lancet 1993; 342: 821-828.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
6. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
7. Pyörälä K, de Backer G, Poole-Wilson P, Wood DA, on behalf of the Task Force. The European Society of Cardiology. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-1331.
8. Enbergs A, Liese A, Heimbach M et al. Secondary prevention of coronary heart disease-ideal versus reality in the Münster EUROASPIRE study population. Z Kardiol 1997; 86: 284-291.
9. Campbell W, Scanlon DM. Bridging the gap between research and practice. The role of continuing medical education. JAMA 1997; 277: 155-156.
10. Walsh JT, Gray D, Keating NA, Cowley AJ, Hampton JR. ACE for whom? Implications for clinical practice of post-infarct trials. Br Heart J 1995; 73: 470-474.
11. Smith J, Channer KS. Increasing prescription of drugs for secondary prevention after myocardial infarction. Br Med J 1995; 311: 917-918.
12. Soumeral SB, McLaughin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of b-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277: 115-121.
13. Brand DA, Newcomer LN, Freiburger A, Tian Hao. Cardiologists' practices compared with practice guideline: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol 1995; 25: 1327-1332.
14. Guidelines for the Evaluation and Management of Heart Failure. Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines Committee on Evaluation and Management of Heart Failure. Circulation 1995; 92: 2764-2784.
15. ASPIRE Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through intervention to reduced events). Principal Results. Heart 1996; 75: 334-342.
16. Whitford DL, Southern AJ. Audit of secondary prophylaxis after myocardial infarction. Br Med J 1994; 309: 1268-1269.